aod9604 wada prohibited list status 2025 World Anti-Doping Agency (WADA) Update WADA's 2025 Prohibited List Comes

Our team often hears this preference cited when discussing various research compounds

Any medication that affects glucose, lipid metabolism, growth hormone signaling, or beta-adrenergic activity could in theory interact, but evidence is absent

Developed by Metabolic Pharmaceuticals in Australia, AOD-9604 was engineered to retain the fat-reducing properties of intact growth hormone while eliminating the undesirable effects on glucose metabolism, insulin sensitivity, and tissue growth

The downstream effects include increased adipose-tissue thermogenesis and reduced fat-storage gene-expression programs

When hormone-sensitive lipase is active, it cleaves the bonds holding triglycerides together, releasing fatty acids into the bloodstream where they can be oxidized for energy